Analysis of the putative role of CR1 in Alzheimer's disease: Genetic association, expression and function

Maria I. Fonseca, Shuhui Chu, Aimee L. Pierce, William D. Brubaker, Richard E. Hauhart, Diego Mastroeni, Elizabeth V. Clarke, Joseph Rogers, John P. Atkinson, Andrea J. Tenner

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Chronic activation of the complement system and induced inflammation are associated with neuropathology in Alzheimer's disease (AD). Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD. Here, anti-CR1 antibodies (Abs) directed against different epitopes of the receptor, were used to localize CR1 in brain, and relative binding affinities of the CR1 ligands, C1q and C3b, were assessed by ELISA. Most Abs tested stained red blood cells in blood vessels but showed no staining in brain parenchyma. However, two monoclonal anti-CR1 Abs labeled astrocytes in all of the cases tested, and this reactivity was preabsorbed by purified recombinant human CR1. Human brain-derived astrocyte cultures were also reactive with both mAbs. The amount of astrocyte staining varied among the samples, but no consistent difference was conferred by diagnosis or the GWAS-identified SNPs rs4844609 or rs6656401. Plasma levels of soluble CR1 did not correlate with diagnosis but a slight increase was observed with rs4844609 and rs6656401 SNP. There was also a modest but statistically significant increase in relative binding activity of C1q to CR1 with the rs4844609 SNP compared to CR1 without the SNP, and of C3b to CR1 in the CR1 genotypes containing the rs6656401 SNP (also associated with the larger isoform of CR1) regardless of clinical diagnosis. These results suggest that it is unlikely that astrocyte CR1 expression levels or C1q or C3b binding activity are the cause of the GWAS identified association of CR1 variants with AD. Further careful functional studies are needed to determine if the variant-dictated number of CR1 expressed on red blood cells contributes to the role of this receptor in the progression of AD, or if another mechanism is involved.

Original languageEnglish (US)
Article numbere0149792
JournalPLoS One
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Alzheimer disease
Polymorphism
single nucleotide polymorphism
Single Nucleotide Polymorphism
Alzheimer Disease
Nucleotides
astrocytes
Association reactions
Astrocytes
Genome-Wide Association Study
Brain
Genes
brain
receptors
antibodies
Antibodies
Anti-Idiotypic Antibodies
Blood
erythrocytes
Erythrocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Fonseca, M. I., Chu, S., Pierce, A. L., Brubaker, W. D., Hauhart, R. E., Mastroeni, D., ... Tenner, A. J. (2016). Analysis of the putative role of CR1 in Alzheimer's disease: Genetic association, expression and function. PLoS One, 11(2), [e0149792]. https://doi.org/10.1371/journal.pone.0149792

Analysis of the putative role of CR1 in Alzheimer's disease : Genetic association, expression and function. / Fonseca, Maria I.; Chu, Shuhui; Pierce, Aimee L.; Brubaker, William D.; Hauhart, Richard E.; Mastroeni, Diego; Clarke, Elizabeth V.; Rogers, Joseph; Atkinson, John P.; Tenner, Andrea J.

In: PLoS One, Vol. 11, No. 2, e0149792, 01.02.2016.

Research output: Contribution to journalArticle

Fonseca, MI, Chu, S, Pierce, AL, Brubaker, WD, Hauhart, RE, Mastroeni, D, Clarke, EV, Rogers, J, Atkinson, JP & Tenner, AJ 2016, 'Analysis of the putative role of CR1 in Alzheimer's disease: Genetic association, expression and function', PLoS One, vol. 11, no. 2, e0149792. https://doi.org/10.1371/journal.pone.0149792
Fonseca, Maria I. ; Chu, Shuhui ; Pierce, Aimee L. ; Brubaker, William D. ; Hauhart, Richard E. ; Mastroeni, Diego ; Clarke, Elizabeth V. ; Rogers, Joseph ; Atkinson, John P. ; Tenner, Andrea J. / Analysis of the putative role of CR1 in Alzheimer's disease : Genetic association, expression and function. In: PLoS One. 2016 ; Vol. 11, No. 2.
@article{9b3430a0692e41068a71b5905f2c9e74,
title = "Analysis of the putative role of CR1 in Alzheimer's disease: Genetic association, expression and function",
abstract = "Chronic activation of the complement system and induced inflammation are associated with neuropathology in Alzheimer's disease (AD). Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD. Here, anti-CR1 antibodies (Abs) directed against different epitopes of the receptor, were used to localize CR1 in brain, and relative binding affinities of the CR1 ligands, C1q and C3b, were assessed by ELISA. Most Abs tested stained red blood cells in blood vessels but showed no staining in brain parenchyma. However, two monoclonal anti-CR1 Abs labeled astrocytes in all of the cases tested, and this reactivity was preabsorbed by purified recombinant human CR1. Human brain-derived astrocyte cultures were also reactive with both mAbs. The amount of astrocyte staining varied among the samples, but no consistent difference was conferred by diagnosis or the GWAS-identified SNPs rs4844609 or rs6656401. Plasma levels of soluble CR1 did not correlate with diagnosis but a slight increase was observed with rs4844609 and rs6656401 SNP. There was also a modest but statistically significant increase in relative binding activity of C1q to CR1 with the rs4844609 SNP compared to CR1 without the SNP, and of C3b to CR1 in the CR1 genotypes containing the rs6656401 SNP (also associated with the larger isoform of CR1) regardless of clinical diagnosis. These results suggest that it is unlikely that astrocyte CR1 expression levels or C1q or C3b binding activity are the cause of the GWAS identified association of CR1 variants with AD. Further careful functional studies are needed to determine if the variant-dictated number of CR1 expressed on red blood cells contributes to the role of this receptor in the progression of AD, or if another mechanism is involved.",
author = "Fonseca, {Maria I.} and Shuhui Chu and Pierce, {Aimee L.} and Brubaker, {William D.} and Hauhart, {Richard E.} and Diego Mastroeni and Clarke, {Elizabeth V.} and Joseph Rogers and Atkinson, {John P.} and Tenner, {Andrea J.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0149792",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Analysis of the putative role of CR1 in Alzheimer's disease

T2 - Genetic association, expression and function

AU - Fonseca, Maria I.

AU - Chu, Shuhui

AU - Pierce, Aimee L.

AU - Brubaker, William D.

AU - Hauhart, Richard E.

AU - Mastroeni, Diego

AU - Clarke, Elizabeth V.

AU - Rogers, Joseph

AU - Atkinson, John P.

AU - Tenner, Andrea J.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Chronic activation of the complement system and induced inflammation are associated with neuropathology in Alzheimer's disease (AD). Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD. Here, anti-CR1 antibodies (Abs) directed against different epitopes of the receptor, were used to localize CR1 in brain, and relative binding affinities of the CR1 ligands, C1q and C3b, were assessed by ELISA. Most Abs tested stained red blood cells in blood vessels but showed no staining in brain parenchyma. However, two monoclonal anti-CR1 Abs labeled astrocytes in all of the cases tested, and this reactivity was preabsorbed by purified recombinant human CR1. Human brain-derived astrocyte cultures were also reactive with both mAbs. The amount of astrocyte staining varied among the samples, but no consistent difference was conferred by diagnosis or the GWAS-identified SNPs rs4844609 or rs6656401. Plasma levels of soluble CR1 did not correlate with diagnosis but a slight increase was observed with rs4844609 and rs6656401 SNP. There was also a modest but statistically significant increase in relative binding activity of C1q to CR1 with the rs4844609 SNP compared to CR1 without the SNP, and of C3b to CR1 in the CR1 genotypes containing the rs6656401 SNP (also associated with the larger isoform of CR1) regardless of clinical diagnosis. These results suggest that it is unlikely that astrocyte CR1 expression levels or C1q or C3b binding activity are the cause of the GWAS identified association of CR1 variants with AD. Further careful functional studies are needed to determine if the variant-dictated number of CR1 expressed on red blood cells contributes to the role of this receptor in the progression of AD, or if another mechanism is involved.

AB - Chronic activation of the complement system and induced inflammation are associated with neuropathology in Alzheimer's disease (AD). Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD. Here, anti-CR1 antibodies (Abs) directed against different epitopes of the receptor, were used to localize CR1 in brain, and relative binding affinities of the CR1 ligands, C1q and C3b, were assessed by ELISA. Most Abs tested stained red blood cells in blood vessels but showed no staining in brain parenchyma. However, two monoclonal anti-CR1 Abs labeled astrocytes in all of the cases tested, and this reactivity was preabsorbed by purified recombinant human CR1. Human brain-derived astrocyte cultures were also reactive with both mAbs. The amount of astrocyte staining varied among the samples, but no consistent difference was conferred by diagnosis or the GWAS-identified SNPs rs4844609 or rs6656401. Plasma levels of soluble CR1 did not correlate with diagnosis but a slight increase was observed with rs4844609 and rs6656401 SNP. There was also a modest but statistically significant increase in relative binding activity of C1q to CR1 with the rs4844609 SNP compared to CR1 without the SNP, and of C3b to CR1 in the CR1 genotypes containing the rs6656401 SNP (also associated with the larger isoform of CR1) regardless of clinical diagnosis. These results suggest that it is unlikely that astrocyte CR1 expression levels or C1q or C3b binding activity are the cause of the GWAS identified association of CR1 variants with AD. Further careful functional studies are needed to determine if the variant-dictated number of CR1 expressed on red blood cells contributes to the role of this receptor in the progression of AD, or if another mechanism is involved.

UR - http://www.scopus.com/inward/record.url?scp=84978946831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978946831&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0149792

DO - 10.1371/journal.pone.0149792

M3 - Article

C2 - 26914463

AN - SCOPUS:84978946831

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0149792

ER -